Clinical trial
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
NCT00095576 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00095576 |
|---|---|
| Title | Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) |
| Official title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | HIV Vaccine Trials Network |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AIDS, HIV Infections |
| Intervention type | Biological, Drug |
| Interventions | Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose), Comparator: placebo |
| Enrollment | 3,000 |
| Start date | Nov 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2009 |
| First posted | Nov 8, 2004 |
| Last update posted | Oct 6, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: